摘要
Accumulating evidence suggests that the transforming growth factor(TGF)-βpathway might be an ideal target for optimizing chimeric antigen receptor(CAR)-T-cell therapy for solid tumors.In Cellular&Molecular Immunology,Liang et al.(2024)reported that CAR-T cells expressing SMAD7 displayed favorable antitumor efficacy and a reduced risk of systemic toxicity.
